Nice summary of recent research results showing the questionable utility of screening patients for CYP2C9 and VKORC1 variants when initiating warfarin therapy. This goes along with my previous post about Boston Children’s efforts in pharmacogenomics.

We are in the early stages of making pharmacogenomics clinically useful. There are going to be bumps in the road, one of the biggest being we find out that knowing certain gene variations doesn’t impact clinical care.